260 related articles for article (PubMed ID: 19336017)
1. Targeting angiogenesis in bladder cancer.
Elfiky AA; Rosenberg JE
Curr Oncol Rep; 2009 May; 11(3):244-9. PubMed ID: 19336017
[TBL] [Abstract][Full Text] [Related]
2. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
English BC; Price DK; Figg WD
Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
[No Abstract] [Full Text] [Related]
3. It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies.
Boere IA; Hamberg P; Sleijfer S
Cancer Sci; 2010 Jan; 101(1):7-15. PubMed ID: 19860846
[TBL] [Abstract][Full Text] [Related]
4. The role of antiangiogenesis therapy: bevacizumab and beyond.
Cortés-Funes H
Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
[TBL] [Abstract][Full Text] [Related]
5. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
[TBL] [Abstract][Full Text] [Related]
6. Targeting angiogenesis in esophagogastric adenocarcinoma.
Okines AF; Reynolds AR; Cunningham D
Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
[TBL] [Abstract][Full Text] [Related]
7. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Horn L; Sandler AB
Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis as a therapeutic target in urothelial carcinoma.
Pinto A; Redondo A; Zamora P; Castelo B; Espinosa E
Anticancer Drugs; 2010 Nov; 21(10):890-6. PubMed ID: 20729712
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Snider KL; Maitland ML
Target Oncol; 2009 Apr; 4(2):67-76. PubMed ID: 19373440
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
Schultheis B; Neumann H; Roy R; Heuer V; Kummer G; Strumberg D
Int J Clin Pharmacol Ther; 2012 Jan; 50(1):72-3. PubMed ID: 22192652
[No Abstract] [Full Text] [Related]
11. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
[TBL] [Abstract][Full Text] [Related]
12. [Targeted therapy for metastatic bladder cancer].
Vom Dorp F; Börgermann C; Rose A; Becker M; Rübben H
Urologe A; 2008 Oct; 47(10):1311-4. PubMed ID: 18587555
[TBL] [Abstract][Full Text] [Related]
13. Drug insight: VEGF as a therapeutic target for breast cancer.
Schneider BP; Sledge GW
Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
[TBL] [Abstract][Full Text] [Related]
14. Targeting angiogenesis in metastatic breast cancer.
Reddy S; Raffin M; Kaklamani V
Oncologist; 2012; 17(8):1014-26. PubMed ID: 22843553
[TBL] [Abstract][Full Text] [Related]
15. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapy for breast cancer.
Nielsen DL; Andersson M; Andersen JL; Kamby C
Breast Cancer Res; 2010; 12(5):209. PubMed ID: 21067536
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic advances in women's cancers.
Carroll AR; Coleman RL; Sood AK
Front Biosci (Schol Ed); 2011 Jan; 3(1):82-97. PubMed ID: 21196359
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis regulated by VEGF and its receptors and its clinical application.
Shibuya M
Rinsho Ketsueki; 2009 May; 50(5):404-12. PubMed ID: 19483401
[No Abstract] [Full Text] [Related]
19. Sorafenib in lung cancer: clinical developments and future directions.
Blumenschein G
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S124-7. PubMed ID: 18520294
[TBL] [Abstract][Full Text] [Related]
20. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Azad NS; Annunziata CM; Steinberg SM; Minasian L; Premkumar A; Chow C; Kotz HL; Kohn EC
Cancer; 2008 Apr; 112(8):1726-32. PubMed ID: 18300236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
